相关实验视频
Updated: Sep 19, 2025
07:42
A Data-Driven Approach to Quantifying Immune States in Sepsis
Published on: February 7, 2025
319
血清白蛋白的表型特异动态及其对败血症死亡率的影响
Gianni Turcato1,2, Arian Zaboli3, Lucia Filippi1
1Department of Internal Medicine, Intermediate Care Unit, Hospital Alto Vicentino (AULSS-7), Santorso, Italy.
Biomarkers in medicine
|June 18, 2025
概括
序列血清白蛋白监测在败血症患者中提供预后价值. 较低的白蛋白水平与较高的死亡率相关,特别是在特定的败血症表型中,指导个性化治疗.
科学领域:
- 关键护理医学 关键护理医学
- 生物化学 生物化学
- 临床病理学 临床病理学
背景情况:
- 败血症是一种危及生命的器官功能障碍,是由宿主对感染反应失调引起的.
- 血清白蛋白水平在重症患者中经常下降,但它们在败血症表型中的预后价值尚未完全理解.
研究的目的:
- 为了评估血清白蛋白测量在患有败血症的患者的预后意义.
- 调查白蛋白动态与不同败血症临床表型之间的关联.
主要方法:
- 一项前性观察性研究包括254名中期护理单位的败血症患者.
- 患者被分为四种败血症表型 (α,β,γ,δ).
- 血清白蛋白水平每天测量五天,以30天死亡率为主要结局. 统计分析包括后勤回归,考克斯模型和AUROC.
主要成果:
- δ败血症类型表现出最低的平均白蛋白 (2.2 g/dL) 和最高的死亡率 (45.4%).
- 类型α具有最高的白蛋白水平和最低的死亡率 (3.6%).
- 专蛋白1g/dL的增加与63%的死亡风险降低有关 (HR 0.37). 专蛋白的预测能力在δ表型中最高 (AUROC高达0.95).
结论:
- 血清白蛋白的连续监测提供了败血症的预后信息.
- 专动态在与内皮功能障碍相关的败血症表型中尤为重要.
- 这些发现表明,基于白蛋白水平和败血症表型的个性化治疗策略的潜力.
相关概念视频
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
123
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
123
01:29Drug Distribution: Plasma Protein Binding
6.8K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
6.8K
01:24Nephrotic Syndrome I : Introduction
37
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
37
01:20Factors Affecting Protein-Drug Binding: Protein-Related Factors
280
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
280
01:22Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
287
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
287
01:29Acute Kidney Injury II: Pathophysiology
101
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
101